Financial StabilityThe company has a solid cash position of approximately $231 million, providing financial stability to support upcoming clinical milestones.
Licensing And Market ExpansionRAPT gaining worldwide development and commercialization rights to RPT904, excluding mainland China, Hong Kong, and Macau, represents a constructive step forward for their broader immunology pipeline.
Market OpportunityRAPT believes food allergy is a significant market opportunity with approximately 17 million patients in the U.S.